相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Alexander W. Hird et al.
PHARMACOLOGY & THERAPEUTICS (2019)
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
James W. Papatzimas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
MCL-1 inhibitors ? where are we now (2019)?
Steven Fletcher
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Targeting cancer's Achilles' heel: role of BCL-2 inhibitors in cellular senescence and apoptosis
Aarti Anantram et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
Ziqian Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL
Xuan Zhang et al.
CHEMICAL COMMUNICATIONS (2019)
MCL-1 inhibition in cancer treatment
Weiguo Xiang et al.
ONCOTARGETS AND THERAPY (2018)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Bcl-2 family proteins are essential for platelet survival
H. Zhang et al.
CELL DEATH AND DIFFERENTIATION (2007)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)